United States: Wilmerhale Represents Trevi Therapeutics In Securing $50M In Series C Financing
Last Updated: August 9 2017

Trevi Therapeutics, Inc. announced that they have completed a Series C financing of $50.5 million led by New Enterprise Associates. The company plans to use the proceeds from the financing to advance the development of Nalbuphine® ER, a drug with a dual agonist/antagonist mechanism of action uniquely suited to treating itch associated in various dermatologic, metabolic, hematologic, and neuropathic conditions.

The WilmerHale deal team counseling Trevi Therapeutics was led by Stuart Falber and included Sam Rothberg and Cara Fonseca.

Read Trevi Therapeutics' press release for more information.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Alan Wilson, Jonathan Wolfman
By Ambassador Charlene Barshefsky, Naboth van den Broek, David Ross, Patrick J. McLain, David Horn
By Frederick Saugman
By Bill Warren
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
By Joseph Mueller, Thomas Saunders, Leslie Pearlson
By WilmerHale
By Robert D. Burke, A. William Caporizzo, Julie Hogan Rodgers, Meghan Walsh
Font Size: